Acetaminophen Aspirin Diphenhydramine
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acetaminophen Aspirin Diphenhydramine
- Acetaminophen + Aspirin + Diphenhydramine: Combination Drug — Insufficient Data for Repurposing Assessment
Acetaminophen + Aspirin + Diphenhydramine: Combination Drug — Insufficient Data for Repurposing Assessment
One-Sentence Summary
Acetaminophen, Aspirin, and Diphenhydramine is a fixed-dose combination commonly used for pain relief with sleep assistance (e.g., nighttime analgesic formulations). The TxGNN model returned no predicted new indications for this combination, and the drug is not registered in the US database as a unified combination product — making a standard repurposing evaluation infeasible at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no registered product found) |
| Predicted New Indication | None (no TxGNN predictions returned) |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not assessable |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No repurposing prediction is available for this combination. Below is background context on the three components to aid future evaluation.
Acetaminophen (paracetamol) is a widely used analgesic and antipyretic. Its exact mechanism is not fully established, but it is believed to inhibit prostaglandin synthesis centrally and may interact with the endocannabinoid system.
Aspirin (acetylsalicylic acid) irreversibly inhibits COX-1 and COX-2, reducing prostaglandin synthesis. At low doses it serves as an antiplatelet agent; at higher doses it provides analgesic and anti-inflammatory effects.
Diphenhydramine is a first-generation H1 antihistamine with significant anticholinergic and sedative properties, commonly used as a sleep aid in OTC nighttime products.
As a fixed triple-dose combination, this product does not have a registered DrugBank ID, and TxGNN could not perform graph-based repurposing analysis. Each component individually has well-characterized pharmacology, but the combination as a single entity returned no signal in this pipeline run.
Clinical Trial Evidence
Currently no related clinical trials registered for this specific combination.
Literature Evidence
Currently no related literature available for this specific combination under the evaluated evidence pack.
US Market Information
No registered products found for the ACETAMINOPHEN + ASPIRIN + DIPHENHYDRAMINE fixed-dose combination in the queried database.
Note: Individual components (acetaminophen, aspirin, diphenhydramine) are widely marketed separately and in various two-component combinations (e.g., acetaminophen + diphenhydramine as Tylenol PM; aspirin + diphenhydramine as Advil PM equivalents). The specific three-component fixed-dose product was not located in this pipeline run.
Safety Considerations
Please refer to the package insert for safety information.
Note: Detailed safety data (key warnings, contraindications, drug-drug interactions) were not returned by this pipeline run. For clinical use, the following are known concerns for this combination:
- Aspirin: Contraindicated in children/adolescents with viral illness (Reye’s syndrome risk); caution in patients on anticoagulants
- Diphenhydramine: Anticholinergic effects; contraindicated in narrow-angle glaucoma, urinary retention, severe COPD
- Acetaminophen: Hepatotoxicity risk at high doses; avoid in severe hepatic impairment; overlapping products common (risk of unintentional overdose)
Conclusion and Next Steps
Decision: Hold
Rationale: This pipeline run returned zero predicted indications, zero registered products, and no safety or MOA data for the three-component combination — there is no actionable repurposing signal to evaluate at this stage.
To proceed, the following is needed:
- Confirm whether this combination exists as a registered NDA product under an alternative search strategy (e.g., search by brand name or search each component individually)
- Obtain a DrugBank ID for the combination or run TxGNN predictions for each individual component separately
- Retrieve MOA data for each component from DrugBank API (data gap DG002)
- Retrieve package insert warnings and contraindications (data gap DG001)
- If repurposing analysis is the goal, consider running TxGNN against acetaminophen, aspirin, and diphenhydramine as individual drug nodes and then assess combination potential
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.